The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

AbbVie acquires Pharmacyclics and Imbruvica

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

AbbVie announced a definitive agreement to acquire Pharmacyclics and its flagship asset Imbruvica for $21 billion. Under the terms of the transaction, announced March 4, AbbVie will pay$261.25 per share, comprised of a mix of cash and AbbVie equity.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account